Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LRRK2 Mutation and Parkinson's Disease: A Functional Neuroimaging and Behavioural Study Characterising the Neurocognitive Phenotype

NCT01424475 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01424475
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01424475 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LRRK2 Mutation and Parkinson's Disease: A Functional Neuroimaging and Behavioural Study Characterising the Neurocognitive Phenotype
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Terminated
Start date
August 11, 2011
Completion date
January 12, 2015
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease